Molnupiravir 200mg caps/PAC-40

Molnupiravir 200mg capsules. HDPE bottle/blister pack of 40 capsules.
Indicative Price 85.00 USD
Disclaimer: The images shown are for illustration purposes only and may not be an exact representation of the product. “No Generic Photo Available" means that there is not an image available for this product.

General description:
Molnupiravir 200mg capsules. HDPE bottle/blister pack of 40 capsules.

In order to access Molnupiravir 200 mg capsules and for more information regarding the same, please refer to the link to the Information Note- Access to COVID-19 Therapeutics:
https://www.unicef.org/sup ply/documents/information-pharmaceutical-products-management-covid-19

Molnupiravir is not recommended in children and adolescents < 18 years of age and pregnant and breastfeeding women.

This product description is standard. It makes no reference to product specific regulatory status, WHO Prequalification status, patent status and pricing policies that may apply at global or country level. For more information, please contact Supply Division at psid@unicef.org

Technical specification:
Each capsule contains: Molnupiravir 200mg.
HDPE bottle/blister pack of 40 capsules.

Therapeutic class:
Antivirals for systemic use

Therapeutic Indications¹: (as per WHO conditional recommendations dated 3rd March 2022)
Adult patients with confirmed (NAAT/PCR or antigen-detection test) non-severe COVID-19 who are > 18 years of age, non-pregnant, and are at highest risk for hospitalization, with symptoms less than 5 days, for
whom alternative treatment options are not accessible or clinically appropriate.

Those at highest risk for disease progression typically are:

• older age (> 60 years)
• have immunosuppression and/or chronic disease.
• unvaccinated against COVID-19.

Immunosuppression and chronic diseases such as: hypertension, diabetes, cardiac disease, chronic lung disease, cerebrovascular disease, dementia, mental disorders, chronic kidney disease, immunosuppression (including HIV), obesity, cancer.

Dosage, Instructions for use:
As directed by the Physician or please refer to the WHO guidelines¹

Reporting of adverse events¹:
Advise patients to enrol and report adverse events to local pharmacovigilance programmes. These are intended to recognize side-effects and potential harms not detected in clinical trials.

1.WHO guidelines: Practical information: Molnupiravir
https://files.magicapp.org/guideline/d0e93c4f-ac0c-4cfb-bb72-13 09caefaadb/files/Molnupiravir_Practical_Informat ion_sheet_28Feb2022_r419344.pdf

Standard total shelf life:
18 months
Actual shelf life at the time of supply may be different.

Storage instructions:
Do not store above 25°C.
Keep out of the reach and sight of children.

Shipping instructions:
This product must be transported between +15°C to +25°C unless otherwise specified by the supplier.

Component of a KIT:

Related products:
S1600005Molnupiravir 200mg caps/PAC-40 pb
S1600006Molnupiravir 200mg caps/PAC-40 gb
S1600007Molnupiravir 200mg caps PAC-4x10 gp
Related Products